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Background
Th ere have been conﬂ icting reports on the eﬃ  cacy of 
recombinant human activated protein C, or drotrecogin 
alfa (activated) (DrotAA), for the treatment of patients 
with septic shock.
Methods
Objective: To test the hypothesis that DrotAA, as com-
pared with placebo, would reduce mortality in patients 
with septic shock.
Design: A randomized, double-blind, placebo-controlled, 
multi center trial, conducted from March 2008 through 
August 2011. Patients were followed until either 90 days 
or death.
Setting: Patients were enrolled from 208 sights in Europe, 
North and South America, Australia, New Zealand, and 
India.
Subjects: Subjects included 1,697 patients with infection, 
systemic inﬂ ammation, and shock who were receiving 
ﬂ uids and vasopressors above a threshold dose for 4 hours.
Intervention: DrotAA (at a dose of 24 μg per kilogram of 
body weight per hour) or placebo for 96 hours.
Outcomes: Death from any cause 28 days after 
randomi zation.
Results
At 28 days, 223 of 846 patients (26.4%) in the DrotAA 
group and 202 of 834 (24.2%) in the placebo group had 
died (relative risk in the DrotAA group, 1.09; 95% 
conﬁ dence interval (CI), 0.92 to 1.28; P  =  0.31). At 90 
days, 287 of 842 patients (34.1%) in the DrotAA group 
and 269 of 822 (32.7%) in the placebo group had died 
(relative risk, 1.04; 95% CI, 0.90 to 1.19; P = 0.56). Among 
patients with severe protein C deﬁ ciency at baseline, 98 
of 342 (28.7%) in the DrotAA group had died at 28 days, 
as compared with 102 of 331 (30.8%) in the placebo group 
(risk ratio, 0.93; 95% CI, 0.74 to 1.17; P = 0.54). Similarly, 
rates of death at 28 and 90 days were not signiﬁ cantly 
diﬀ erent in other predeﬁ ned subgroups, including 
patients at increased risk for death. Serious bleeding 
during the treatment period occurred in 10 patients in 
the DrotAA group and 8 in the placebo group (P = 0.81).
Conclusions
DrotAA did not signiﬁ cantly reduce mortality at 28 or 90 
days, as compared with placebo, in patients with septic 
shock.
Commentary
Sepsis has been described as a multisystem process 
involving a dysregulated host response that can lead to 
organ dysfunction, cardiovascular collapse and death [1]. 
Endogenous activated protein C is believed to play a role 
in many of the pathways thought to be integral to the 
septic response, including proinﬂ ammatory, procoagu-
lant, and apoptotic signals [2]. When the Recombinant 
Human Activated Protein C Worldwide Evaluation in 
Severe Sepsis (PROWESS) study showed a 28-day mor-
tality decrease of 6.1% with drotrecogin alpha acti vated 
(DrotAA) administration in patients with severe sepsis 
[2], the Food and Drug Administration (FDA) and the 
European Medicines Agency (EMEA) approved the drug 
for treatment of high-risk septic patients. Approval 
criteria were based on post hoc reanalysis of PROWESS 
by the FDA; DrotAA was eﬃ  cacious only in the sickest 
patients with severe sepsis - those with multiorgan failure © 2010 BioMed Central Ltd
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and Acute Physiologic and Chronic Health Evaluation 
(APACHE) score ≥25 [3].
PROWESS-SHOCK was a randomized, double-blind, 
placebo-controlled trial designed to show whether 
DrotAA administration improves 28-day mortality in 
patients with septic shock. Using an intention-to-treat 
analysis, they reported no decrease in 28-day or 90-day 
mortality in patients with septic shock who received 
DrotAA compared to those who received placebo. Th ere 
was also no diﬀ erence in 28-day mortality in subgroups 
based on baseline organ dysfunction, protein C deﬁ ciency 
severity, and time from vasopressor-to-infusion onset. 
Th ere was a 2.8% increase in at least one serious event by 
day 28 in the DrotAA group compared to placebo, with a 
trend toward statistical signiﬁ cance (P  =  0.11). All of 
these events were intraluminal or compartmental hemor-
rhage in at least one organ (Table S6 in the supplemental 
appendix of the study by Ranieri and colleagues).
Th ere are many strengths built into the design of this 
trial. In keeping with a priori objectives, the PROWESS-
SHOCK investigators were successful in recruiting very 
sick patients. End-organ hypoperfusion or dysfunction 
was required according to the inclusion criteria, and 
subjects needed to be on vasopressors that could not be 
weaned. Th e mean lactate level was 3.3 mmol/L in both 
placebo and treatment groups. Eighty-four percent of the 
patients in PROWESS-SHOCK had dysfunction of at 
least 2  organs, compared to 45% in the PROWESS trial 
[2]. Th e investigators were also very thorough and trans-
parent in their study design and analysis. Th e overall 
mortality in the trial was 27%, lower than the anticipated 
mortality of 35% based on septic shock patients from 
PROWESS [4]. Th ey were able to retain statistical power 
by recruiting 196 additional patients using an a priori 
mechanism to increase enrollment if overall mortality 
was less than 30%. Th e PROWESS-SHOCK investigators 
were very conservative with any decision to stop the 
study for eﬃ  cacy. Th e decision to stop PROWESS for 
eﬃ  cacy became controversial because it may have over-
estimated the treatment eﬀ ect [5]. Th e PROWESS-
SHOCK investigators required what they called ‘over-
whelm ing eﬃ  cacy’  - P < 0.001 and at least 250 deaths  - 
for early trial termination [4].
Th is study has few recognizable ﬂ aws, but one could 
question whether study design choices or ﬁ ndings had an 
impact on the outcome of PROWESS-SHOCK. Some 
have argued that the study may have been underpowered 
to detect its primary outcome [6]. However, there was 
never a detectable diﬀ erence in mortality during any data 
safety monitoring checks. In fact, the study concluded 
with a 2.2% higher mortality in the treatment group, 
though statistically insigniﬁ cant. It is diﬃ  cult to believe 
that the study would show a mortality beneﬁ t with 
DrotAA if more patients were enrolled. Some have 
suggested that the PROWESS-SHOCK investigators 
should have administered DrotAA earlier for better 
eﬃ  cacy [7]. Th ey argue that by waiting for the develop-
ment of refractory shock, the investigators may have 
missed the ideal window for DrotAA administration. 
However, the development of septic shock and organ 
dysfunction takes time, and to date the one study of 
DrotAA administration to septic patients with less severe 
disease showed no beneﬁ t [8]. Th e sickest patients with 
refractory septic shock were the last group of septic 
patients, for which little data existed about potential 
eﬃ  cacy. Given the division in the critical care community, 
the investigators needed to select this group for study [4].
Do we believe PROWESS or PROWESS-SHOCK? Th ey 
both may have been correct. Sepsis management has 
improved between the times these studies were pub-
lished. Th e implementation of sepsis bundles in many 
hospital settings has been associated with decreased 
mortality [9]. Th e attributable beneﬁ t DrotAA may have 
once had on mortality could have been lost because of 
improved overall sepsis care. Th e heterogeneous nature 
of the sepsis population could also be a reason for the 
inconsistencies between PROWESS and PROWESS-
SHOCK [10]. Sepsis is not a single disease entity but a 
clinical syndrome that is a common endpoint among 
many causes of infection. Th ere were about 10% more 
patients with abdominal causes of sepsis in PROWESS-
SHOCK compared to PROWESS, and proportionately 
less with pneumonia as a cause (Table S3 in the supple-
mentary appendix of the study) [2]. Perhaps a diﬀ erence 
in the case mix between the two trials contributed to the 
diﬀ erence in study results. While one meta-analysis has 
since evaluated DrotAA eﬃ  cacy and safety and shown 
possible beneﬁ t, less than 10% of the patients represented 
were from randomized con trolled trials [6].
Recommendation
Th is study showed a higher risk of bleeding and no 
mortality beneﬁ t from DrotAA in septic shock. DrotAA 
should no longer be recommended in sepsis guidelines as 
a standard of care.
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